Trials / NCT04278131
BS01 in Patients With Retinitis Pigmentosa
Recruiting now Phase 1 / Phase 2 Optogenetics, Gene therapy
- Sponsor
- Bionic Sight LLC
- Treatment
- BS01
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 20 participants
- Started
- 2020-02-06
- Main results expected
- 2026-12-30
- Results posted
- Not yet
- Record last updated
- 2026-01-23
What the study is testing
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Where it runs
United States (1)
- New Jersey Retina, Teaneck, New Jersey (recruiting now)